Latest News

Living Well with MS – Our NEW resources

January 31, 2024 | Education, Life with MS, Progressive, Support, Symptoms, Training, Treatments

We are thrilled to share with you our newest resources. Our Living Well with MS (LWWMS) booklet will provide you with a good overview of what multiple sclerosis is, what causes it, how it is diagnosed, the symptoms and treatment […]


Media Release: “Relief” over Pharmac Decision to Fund First-Ever Treatment for Debilitating Form of Multiple Sclerosis

September 4, 2023 | Advocacy, Media, Progressive, Treatments

A seven year battle on behalf of hundreds of people living with the most debilitating form of Multiple Sclerosis has been won – with Pharmac agreeing to fund Aotearoa New Zealand’s first ever treatment for the disease variant  from October […]


MS in the News: Funded treatment for primary progressive multiple sclerosis

June 26, 2023 | Media, Progressive

Te Pātaka Whaioranga – Pharmac has started a consultation today for widening access for two treatments; ocrelizumab (branded as Ocrevus) as the first funded treatment for primary progressive multiple sclerosis, and emicizumab (branded as Hemlibra) for the treatment of all […]


‘Exhaustion and dread’ : Desperate carer calls for change

June 26, 2023 | Advocacy, Carer, Carers, Life with MS, Media, Petition, Progressive, Uncategorised

Speaking in support of the Carers Alliance petition, Maxine Hall, a carer for her husband with Multiple Sclerosis, speaks of her struggles and hopes that this campaign will at least raise awareness. View original article on Otago Daily Times: https://www.odt.co.nz/news/dunedin/exhaustion-and-dread-desperate-carer-calls-change […]


Major announcement: Pharmac Initiates Consultation to fund Ocrelizumab for Primary Progressive MS.

June 22, 2023 | Advocacy, Funding, Media, Progressive

Multiple Sclerosis New Zealand (MSNZ) is delighted to share that Pharmac have commenced consultation to fund Ocrelizumab for Primary Progressive MS. Currently, those with PPMS have no access to any disease modifying therapies. Ocrelizumab has been proven in trials to […]